Abstract
Inhaled drugs have been recognized for their great potential for improved drug delivery, but so far only a fraction of their potential is benefiting clinical practice. Many new promising drug candidates are in development pipelines and some of them are approaching processes of regulatory agencies. Overall, investigation in inhalation drug development is intense. Inhalation administration route provides benefits over other routes of administration, e.g. avoidance of firstpass- metabolism, and convenience for patients in administrations without repeated injections. However, drug development of inhaled substances is complicated and usually development times are longer than ordinary drug development. Additional investigational needs in development of inhaled drugs are dealing with formulation, devices and variability of respiratory function between human subjects. Radiopharmaceuticals provide invaluable tool to explore these issues noninvasively. First, radiopharmaceuticals can be used in vitro for proof of concept studies. Second, they are used to resolve depository issues, as well as to give timeframe for clearance of substances in target organs. Third, radiopharmaceuticals new potential use is focused on extending non-invasive imaging technique towards true pharmacokinetic modelling via calculations of target organ follow-up and exposure. Exposure estimates of a particular drug candidate make safety evaluation feasible early in the drug development. Safety issues can be resolved by investigating exposures of target organs, and depository and absorption issues in airways.
Keywords: Inhaled drugs, firstpass- metabolism, drug development, non-invasive imaging technique, pharmacokinetic modelling
Current Pharmaceutical Design
Title: Role of Radiopharmaceuticals in Development of Inhaled Drugs
Volume: 15 Issue: 9
Author(s): Antti P. Jekunen
Affiliation:
Keywords: Inhaled drugs, firstpass- metabolism, drug development, non-invasive imaging technique, pharmacokinetic modelling
Abstract: Inhaled drugs have been recognized for their great potential for improved drug delivery, but so far only a fraction of their potential is benefiting clinical practice. Many new promising drug candidates are in development pipelines and some of them are approaching processes of regulatory agencies. Overall, investigation in inhalation drug development is intense. Inhalation administration route provides benefits over other routes of administration, e.g. avoidance of firstpass- metabolism, and convenience for patients in administrations without repeated injections. However, drug development of inhaled substances is complicated and usually development times are longer than ordinary drug development. Additional investigational needs in development of inhaled drugs are dealing with formulation, devices and variability of respiratory function between human subjects. Radiopharmaceuticals provide invaluable tool to explore these issues noninvasively. First, radiopharmaceuticals can be used in vitro for proof of concept studies. Second, they are used to resolve depository issues, as well as to give timeframe for clearance of substances in target organs. Third, radiopharmaceuticals new potential use is focused on extending non-invasive imaging technique towards true pharmacokinetic modelling via calculations of target organ follow-up and exposure. Exposure estimates of a particular drug candidate make safety evaluation feasible early in the drug development. Safety issues can be resolved by investigating exposures of target organs, and depository and absorption issues in airways.
Export Options
About this article
Cite this article as:
Jekunen P. Antti, Role of Radiopharmaceuticals in Development of Inhaled Drugs, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787582002
DOI https://dx.doi.org/10.2174/138161209787582002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Paliroden (SR57667B) and Xaliproden on Adult Brain Neurogenesis
Current Alzheimer Research Lipid Based Aqueous Core Nanocapsules (ACNs) for Encapsulating Hydrophillic Vinorelbine Bitartrate: Preparation, Optimization, Characterization and In vitro Safety Assessment for Intravenous Administration
Current Drug Delivery Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Nanobiotechnological Approaches to Overcome Drug Resistance in Breast Cancer
Current Cancer Drug Targets Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer)
Current Cancer Drug Targets Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry Therapy Related Markers and Response Prediction Towards Multimodal Treatment of Carcinomas of the Upper Gastrointestinal Tract
Current Pharmacogenomics and Personalized Medicine Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Intriguing Classes of Acridine Derivatives as DNA-binding Antitumour Agents: From Pyrimido[5,6,1-de]acridines to Bis(acridine-4-carboxamides)
Medicinal Chemistry Reviews - Online (Discontinued) Toxicity of 11 Metal Oxide Nanoparticles to Three Mammalian Cell Types <i>In Vitro</i>
Current Topics in Medicinal Chemistry Smell and Taste Disorders Resulting from Cancer and Chemotherapy
Current Pharmaceutical Design Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Role of Pemetrexed and Platinums Combination in Patients with Non- Small Cell Lung Cancer
Current Drug Targets The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Fetal Mesenchymal Stem Cells in Cancer Therapy
Current Stem Cell Research & Therapy Biological Applications of ZnO Nanoparticles
Current Molecular Imaging (Discontinued) Recent Progress in Therapeutic and Diagnostic Applications of Lanthanides
Mini-Reviews in Medicinal Chemistry